Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies.
about
Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform DependentLocalizing Carbohydrate Binding Sites in Proteins Using Hydrogen/Deuterium Exchange Mass Spectrometry.Influence of Linker Length on Conformational Preferences of Glycosylated Sugar Amino Acid Foldamers.Immunobiology of liver xenotransplantation.Acceleration of reaction in charged microdroplets.Fucosylation in prokaryotes and eukaryotes.Glyconanomaterials for biosensing applications.Xenotransplantation literature update November-December 2005.Structural biology of carbohydrate xenoantigens.Microfluidics-Mass Spectrometry of Protein-Carbohydrate Interactions: Applications to the Development of Therapeutics and Biomarker Discovery.Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies.Sequence and Architectural Control in Glycopolymer Synthesis.Revised domain structure of ulvan lyase and characterization of the first ulvan binding domain.Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.Salmonella Typhimurium Enzymatically Landscapes the Host Intestinal Epithelial Cell (IEC) Surface Glycome to Increase Invasion.A murine monoclonal antibody to glycogen: characterization of epitope-fine specificity by saturation transfer difference (STD) NMR spectroscopy and its use in mycobacterial capsular α-glucan research.Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy.Chemoselective ligation reaction of N-acetylglucosamine (NAG) with hydrazide functional probes to determine galactosyltransferase activity by MALDI mass spectrometry.Screening for concanavalin A binders from a mannose-modified α-helix peptide phage library.Assigning kinetic 3D-signatures to glycocodes.Synthetic Assembly of Mannose Moieties Using Polymer Chemistry and the Biological Evaluation of Its Interaction towards Concanavalin A.A new generation of carbohydrate-based therapeutics: recombinant mucin-type fusion proteins as versatile inhibitors of protein-carbohydrate interactions.Three-dimensional potential energy surface of selected carbohydrates' CH/π dispersion interactions calculated by high-level quantum mechanical methods.Exploiting glycan topography for computational design of Env glycoprotein antigenicity.Epidermal LysM receptor ensures robust symbiotic signalling in Lotus japonicus.
P2860
Q28547866-8E5A32C3-20AB-475C-9787-43199143F2F6Q30379769-FB0BE744-4F14-45C7-9CBB-76C3EC89E8B1Q31114822-6A31DDDC-E8F4-4849-8DBE-0C44D5168789Q33403888-6A749111-79C6-4B72-87A4-9EFCF8E45D94Q33731798-742D7E78-B1C0-4BFF-A00E-6426D1044C8DQ34566205-2E02D61E-BEB1-47DC-A0EC-39E93AF460DBQ36260313-27FF8B4C-942E-4464-BD02-5F1CD3D6B560Q36453392-93F9A7C6-93AB-411E-9598-D63A331BA1B2Q37547263-BCB76EFE-EC57-4FF8-9068-09C208EB3E07Q38287513-F6F29DA3-CA75-4F0F-8FA7-96C73DB8A059Q38298848-A74F23E1-9C4B-46A2-A7EB-DB0D1F6EE425Q38660455-151B6252-35C5-445E-B844-E8B7D5FF4E6AQ38741724-CDBCBF93-4C81-474B-80BB-7BADB5C4B13EQ38755916-C3CE4A57-A501-45CD-A5AF-CCAC1D50923AQ40501498-8909CD37-AE48-4673-BEEB-1FFBD161D0A8Q41232382-805BAC30-9A8D-49FF-9F6C-1B21F8C96949Q43083591-8625FC5E-6DF2-4E27-871E-5857954D37AAQ46171449-B6C13890-99CC-4816-B9B0-A2035889249FQ47717465-0F8B259B-B66A-486E-94DB-0FB0B659AFFEQ48024453-C95E7ED0-0597-453E-8B65-8691F272F5F2Q51036255-FF91C3D9-CC5F-4220-9971-4D794BBD0211Q51171028-7F11FC8C-F767-4D70-B198-B8D6EDF3BA74Q51608376-30BD9FBA-CB23-4061-B625-0F6386C725BAQ52314288-A40705CC-950C-46A9-9ED5-9C3B8C42FCB9Q55473358-975AA9A4-40AF-473B-B742-068D4C51D067
P2860
Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Characteristics of protein-car ...... based antirejection therapies.
@ast
Characteristics of protein-car ...... based antirejection therapies.
@en
type
label
Characteristics of protein-car ...... based antirejection therapies.
@ast
Characteristics of protein-car ...... based antirejection therapies.
@en
prefLabel
Characteristics of protein-car ...... based antirejection therapies.
@ast
Characteristics of protein-car ...... based antirejection therapies.
@en
P2093
P2860
P1476
Characteristics of protein-car ...... based antirejection therapies.
@en
P2093
Anki Gustafsson
Jan Holgersson
Michael E Breimer
P2860
P304
P356
10.1111/J.1440-1711.2005.01373.X
P577
2005-12-01T00:00:00Z